Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
暂无分享,去创建一个
[1] M. Waltham,et al. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma , 2023, Blood advances.
[2] Xuejiao Han,et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies , 2022, Journal of Hematology & Oncology.
[3] A. Rosenwald,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.
[4] A. Amiot,et al. Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study , 2022, Leukemia & lymphoma.
[5] Y. Nishimura,et al. Clinical characteristics and outcomes of IgG4‐positive marginal zone lymphoma: Systematic scoping review , 2022, Pathology international.
[6] M. Du,et al. CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development , 2022, Haematologica.
[7] J. R. Plaça,et al. Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome , 2022, Cancers.
[8] Sander R. Dubovy,et al. The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways , 2021, Cancer research communications.
[9] R. Marcus,et al. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma , 2021, Clinical Cancer Research.
[10] A. Tzankov,et al. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin , 2021, Virchows Archiv.
[11] M. Du,et al. GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma. , 2021, Blood.
[12] C. Copie-Bergman,et al. Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma , 2021, Cancers.
[13] A. Akarca,et al. Thyroid MALT lymphoma: self-harm to gain potential T-cell help , 2021, Leukemia.
[14] Jianmin Ma,et al. Clinical Features and Prognoses of IgG4-Positive and IgG4-Negative Lacrimal Lymphomas , 2021, Frontiers in Oncology.
[15] S. Chuang,et al. Primary IgG4‐producing extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) in the cavernous sinus: A mimicker of IgG4‐related disease/hypertrophic pachymeningitis , 2021, Pathology international.
[16] D. Kim,et al. Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis , 2021, Helicobacter.
[17] C. Flowers,et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. , 2020, Blood advances.
[18] A. Amiot,et al. Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab. , 2020, Clinical lymphoma, myeloma & leukemia.
[19] M. Raderer,et al. Immunomodulatory treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma) , 2020, Hematological oncology.
[20] R. Bende,et al. Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG , 2020, Arthritis & rheumatology.
[21] A. Salar,et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] R. Gascoyne,et al. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses , 2019, Haematologica.
[23] G. Vassiliou,et al. Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites , 2018, Haematologica.
[24] M. Mayerhoefer,et al. Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma) , 2018, Hematological oncology.
[25] Juan F. García,et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. , 2017, Blood.
[26] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[27] S. Cogliatti,et al. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4‐34 usage in mucosa‐associated lymphoid tissue lymphoma , 2017, The Journal of pathology.
[28] C. Flowers,et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. , 2017, Blood.
[29] C. von Buchwald,et al. Association between Hashimoto’s Thyroiditis and Thyroid Cancer in 64,628 Patients , 2017, Front. Oncol..
[30] G. Salles,et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Du. MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. , 2017, Best practice & research. Clinical haematology.
[32] A. Ferreri,et al. Bacteria associated with marginal zone lymphomas. , 2017, Best practice & research. Clinical haematology.
[33] R. Greil,et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. , 2017, Blood.
[34] M. Wei,et al. The B‐cell‐activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa‐associated lymphoid tissue lymphoma without t(11;18)(q21;q21) , 2016, The Journal of pathology.
[35] M. Du. MALT lymphoma: A paradigm of NF-κB dysregulation. , 2016, Seminars in cancer biology.
[36] A. Ferreri,et al. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) , 2016, CA: a cancer journal for clinicians.
[37] R. Bende,et al. Stereotypic Rheumatoid Factors That Are Frequently Expressed in Mucosa‐Associated Lymphoid Tissue–Type Lymphomas Are Rare in the Labial Salivary Glands of Patients With Sjögren's Syndrome , 2015, Arthritis & rheumatology.
[38] A. Chott,et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up , 2015, Annals of Hematology.
[39] Juan F. García,et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. , 2014, The Lancet. Haematology.
[40] M. Mokry,et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. , 2014, Blood.
[41] R. Gascoyne,et al. The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.
[42] M. Raderer,et al. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. , 2013, Blood.
[43] M. Paulli,et al. Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] R. Zhong,et al. Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis , 2013, Annals of the rheumatic diseases.
[45] A. Amiot,et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study , 2013, Leukemia & lymphoma.
[46] W. Dolak,et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.
[47] M. Kersten,et al. Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment , 2012, Leukemia.
[48] I. Lossos,et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities , 2012, Modern Pathology.
[49] I. Lossos,et al. Biased Use of the IGHV4 Family and Evidence for Antigen Selection in Chlamydophila psittaci-Negative Ocular Adnexal Extranodal Marginal Zone Lymphomas , 2011, PloS one.
[50] H. Matsumoto,et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan , 2011, Gut.
[51] K. Yeh,et al. t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement , 2011, Cancer Chemotherapy and Pharmacology.
[52] F. Mégraud,et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT , 2011, Gut.
[53] Francesco Bertoni,et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. , 2011, Blood.
[54] P. Van Loo,et al. Cleavage of NIK by the API2-MALT1 Fusion Oncoprotein Leads to Noncanonical NF-κB Activation , 2011, Science.
[55] S. Cogliatti,et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis , 2010, Leukemia.
[56] I. Sobhani,et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up , 2010, Leukemia & lymphoma.
[57] C. Doglioni,et al. Chlamydial infection: the link with ocular adnexal lymphomas , 2009, Nature Reviews Clinical Oncology.
[58] H. Tagawa,et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. , 2009, Blood.
[59] H. Müller-Hermelink,et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation‐negative MALT lymphoma of the ocular adnexa and salivary glands , 2009, The Journal of pathology.
[60] C. Copie-Bergman,et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial , 2009, British journal of haematology.
[61] H. Ye,et al. BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma , 2008, International journal of hematology.
[62] A. Vincent-Salomon,et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? , 2008, Anti-cancer drugs.
[63] A. Banham,et al. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control , 2008, Modern Pathology.
[64] D. de Jong,et al. Dissemination patterns in non-gastric MALT lymphoma , 2008, Haematologica.
[65] M. Du. MALT lymphoma : recent advances in aetiology and molecular genetics. , 2007, Journal of clinical and experimental hematopathology : JCEH.
[66] A. Chott,et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course , 2007, Leukemia.
[67] W. Fischbach,et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series , 2007, Gut.
[68] A. Banham,et al. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation , 2007, Gut.
[69] A. Chott,et al. Reverse Transcription-PCR for t(11;18)(q21;q21) Staging and Monitoring in Mucosa-Associated Lymphoid Tissue Lymphoma , 2006, Clinical Cancer Research.
[70] K. Turetschek,et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] M. Du,et al. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management , 2006, Gut.
[72] A. Chott,et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas , 2005, Gut.
[73] T. Molina,et al. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication , 2005, Gut.
[74] V. Abraira,et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] K. Yeh,et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). , 2005, Blood.
[76] C. Copie-Bergman,et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] C. Doglioni,et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] E. Pedrinis,et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] T. Al-Saleem,et al. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. , 2005, Blood.
[80] A. Nicholson,et al. MALT lymphoma with t(14;18)(q32;q21)/IGH‐MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression , 2005, The Journal of pathology.
[81] R. Siebert,et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites , 2004, Leukemia.
[82] A. Chott,et al. Translocation t(11;18)(q21;q21) Is Not Predictive of Response to Chemotherapy with 2CdA in Patients with Gastric MALT Lymphoma , 2004, Oncology.
[83] Ming-Qing Du,et al. MALT lymphoma: from morphology to molecules , 2004, Nature Reviews Cancer.
[84] M. Boiocchi,et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. , 2004, Journal of the National Cancer Institute.
[85] A. Nicholson,et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. , 2003, Blood.
[86] M. D’Elios,et al. Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. , 2003, Microbes and infection.
[87] M. Dyer,et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. , 2003, Blood.
[88] T. Molina,et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. , 2001, Gastroenterology.
[89] A. Chott,et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] Ming-Qing Du,et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy , 2001, The Lancet.
[91] M. Dyer,et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. , 2000, The American journal of pathology.
[92] Jeffrey E. Lee,et al. Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial , 1999, Annals of Internal Medicine.
[93] M. Fujishima,et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. , 1998, The American journal of pathology.
[94] P. Isaacson,et al. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. , 1997, The American journal of pathology.
[95] T. Greiner,et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[96] H. Müller-Hermelink,et al. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. , 1997, The American journal of pathology.
[97] L. Cerroni,et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. , 1997, Journal of the American Academy of Dermatology.
[98] P. Isaacson,et al. HELICOBACTER PYLORI‐SPECIFIC TUMOUR‐INFILTRATING T CELLS PROVIDE CONTACT DEPENDENT HELP FOR THE GROWTH OF MALIGNANT B CELLS IN LOW‐GRADE GASTRIC LYMPHOMA OF MUCOSA‐ASSOCIATED LYMPHOID TISSUE , 1996, The Journal of pathology.
[99] T. C. Diss,et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.
[100] P. Isaacson,et al. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori , 1993, The Lancet.
[101] P. Isaacson,et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma , 1991, The Lancet.
[102] G. Friedman,et al. Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.
[103] H. Stein,et al. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. , 1991, Journal of the American Academy of Dermatology.
[104] T. Suchi,et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. , 1985, Japanese journal of cancer research : Gann.
[105] P. Isaacson,et al. Malignant lymphoma of mucosa‐associated lymphoid tissue. A distinctive type of B‐cell lymphoma , 1983, Cancer.
[106] E. Zucca,et al. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) , 2021, Hematologic Malignancies.
[107] Y. J. Choi. Gastric Extranodal Marginal Zone B-Cell Lymphoma of MALT , 2016 .
[108] J. Andreu,et al. Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: a systematic literature review and meta-analysis , 2014, Rheumatology International.
[109] K. Stamatopoulos,et al. Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation , 2012, Leukemia.
[110] O. Lortholary,et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.